Review

Unified Approaches in Modern Drug Delivery Covering Lipid Based Nanocarriers Controlled Release Mechanisms and Innovative Tablet Technologies

Ashutosh Sengar *

Posted Date: 18 November 2025

doi: 10.20944/preprints202511.1343.v1

Keywords: lipid-based nanocarriers; controlled-release systems; advanced oral dosage forms; targeted drug delivery; nanotechnology in pharmaceuticals

 doi:10.20944/preprints202511.1343.v1

Review

Unified Approaches in Modern Drug Delivery Covering Lipid Based Nanocarriers Controlled Release Mechanisms and Innovative Tablet Technologies

Ashutosh Sengar

Assistant Professor, Dept. of Pharmaceutics, S.R. Group of Institutions, Jhansi, U.P.;
ashutoshsengar26567@gmail.com

Abstract

The drug delivery system of today is made up of heap of innovations like lipid-based nanocarriers, controlled-release technologies, and rapidly developing oral dosage forms. The present article is the first to provide an exhaustive coverage of the latest methods along with their benefits that include greater therapeutic effectiveness, better patient compliance, and flexibility in formulation. One of these methods is the use of lipid nanoparticles: liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and other vesicular systems which are responsible for the better solubility, permeability and stability of difficult bioactive molecules. Their compatibility with oral dosage forms has resulted in improving gastrointestinal absorption, targeted delivery, and sustained exposure. The controlled-release systems have come a long way too, offering the most sophisticated modulation of drug release through diffusion, erosion, osmotic, and swelling mechanisms. The systems yield predictable pharmacokinetic profiles and reduce dosing frequency, while oral controlled-release strategies' innovations open the door for an application in various therapeutic categories. In the meantime, oral dosage technologies such as fast-dissolving tablets, effervescent systems, QbD-based solid dosage forms, and 3D-printed tablets are signs of the growing patient-centric and customizable therapeutic design themes. The amalgamation of nanocarriers with state-of-the-art oral and controlled-release systems leads to the formation of synergistic platforms that are capable of delivering drugs with very high bioavailability and targeted delivery. Future directions indicate the pathways of transporter-mediated absorption, AI-assisted formulation optimization, and new capsule-based inventions as revolutionary players of drug delivery in the next generation. The advances mentioned above form a united pattern for future pharmaceutical development that is based on creative ideas, accuracy, and improved efficiency in therapy.

Keywords: lipid-based nanocarriers; controlled-release systems; advanced oral dosage forms; targeted drug delivery; nanotechnology in pharmaceuticals

1. Introduction

The drastic change in pharmaceutical drug delivery has come to pass through the use of nanocarriers and liposomes alongside targeted formulations and new tablet technologies which have become more common thus having a tremendous impact on the precision of treatments and the outcome of patients. Current situation analyses indicate that the delivery innovations of the drugs are not only restricted to the aspect of bioavailability but also to the integration of various systems that consist of liposomal carriers, nanoparticle systems, and orally optimized dosage forms for controlled, site-specific release [1]. Besides, these developments also reflect the growing need for drug delivery systems that can overcome solubility, permeability, and stability problems while still maintaining a consistent therapeutic profile.

 doi:10.20944/preprints202511.1343.v1

Liposomal and nanoparticle research along with other areas have pushed the current trend of hybrid tools in disease delivery to the emergence of strategies that can break through biochemical and physiological barriers. Research reveals that the design of liposomes, nanostructured carriers, and oral delivery matrices is directed towards providing better encapsulation efficiency, longer circulation time, and controlled drug release - all of which are necessary for both chronic and acute treatments [2]. Besides, the integration of these systems into the oral and controlled-release designs brings forth the possibility of more predictable pharmacokinetic and pharmacodynamic behaviors which in turn results in reduced frequency of dosing and hence, improved patient compliance.

Additionally, the parallel research has made it quite clear that vesicular carriers, solid lipid nanoparticles, and polymer-based systems are of utmost importance with regard to the issues faced by conventional formulations. These delivery platforms have been extensively investigated as to their processes for enhancing stability, protecting delicate molecules, and facilitating either lymphatic uptake or gastrointestinal tract absorption through targeted pathways [3]. Delivery methods with these innovations are strategically shifting towards more reliable routes, especially for drugs that are poorly soluble, have low permeability, or are easily degraded.

Liposomes are still one of the most explored and accepted nanocarrier systems in clinics, pointing to a wide range of their therapeutic applicability through approved pharmaceutical products. Liposomes are the central subject in today's delivery research due to their biocompatibility, encapsulating ability for both hydrophilic and lipophilic drugs, and regulatory acceptance [4]. At the same time, the regulators view this trend as the shifting focus towards quality, scalability, and safety— which are the factors that make it easier for liposomal technologies to move from the laboratory to the clinic.

Moreover, lipid-based nano drug delivery systems consisting of solid lipid nanoparticles, nanostructured lipid carriers, micelles, and other lipidic assemblies are the ones that have come forward as the most effective solutions to improve the oral administration of drugs and to overcome the hurdles linked to the poor solubility and permeability of the molecules. These types of systems endow the molecules with increased gastrointestinal transport, targeted uptake, and sustained release in such a way that their use becomes possible over a wide range of therapeutic categories [5]. All these developments together reveal the strong interdisciplinary background which the unified, modern drug delivery approaches are still evolving to the present day.

2. Lipid-Based Nanocarriers

Because of the growing demand for drug delivery systems that can overcome poor intestinal absorption and the fact that their lipid-based nanoparticles can protect sensitive therapeutic molecules, they have become the central platform in oral drug delivery. The studies report that these systems not only retain the peptides and proteins in the harsh gastrointestinal environment but also increase their absorption through the epithelial barriers which leads to significantly higher bioavailability profiles in oral administration [6]. Thus, these advantages of lipid nanoparticles make them very attractive candidates for the delivery of macromolecules and biotherapeutics, where traditional formulations usually fail.

Moreover, recent breakthroughs have further underscored the importance of transporter-mediated uptake in refining the use of oral lipid-based nanocarriers. It has been found that the systems designed with nanoparticles such that they interact with the specific intestinal transport pathways can lead to the absorption and delivery of the drug to the targeted area, i.e., the disease specific tissue, that is not only efficient but also faster [7]. Thus, the evolution of solving the drug delivery problem through transporter-guided design is indicative of a shift in the drug absorption strategy from passive to more active one.

In addition, the studies conducted on nano- and micro-lipid systems are revealing their ability to overcome the limitations of solubility and permeability connected with a number of small-molecule drugs. The first action of lipidic structures such as micelles, solid lipid particles, and nanostructured carriers is the enhancement of dissolution, which is followed by the protection of

 doi:10.20944/preprints202511.1343.v1

labile molecules and promotion of lymphatic uptake, thereby leading to improved systemic exposure and therapeutic reliability [8]. This strategy makes the range of lipid-based technologies' applicability wider to the whole BCS class II and IV drugs.

Lipid nanoparticles have been indicated to not only enhance the oral bioavailability of both kinds of molecules, i.e., hydrophobic and hydrophilic, considerably but also to show their worth by doing so in a manner that the resulting product would be less frequent and less variable in dosing thus making it more patient friendly [9]. The consistent outcome of such research points to the multifunctionality of lipid nanoparticles in overcoming various pharmacokinetic hurdles.

Moreover, the utilization of lipid nanocarrier systems has been extended beyond oral administration into the domain of targeted drug delivery, such as in treatment of colorectal cancer. Colorectal-targeted nanoparticles compared to conventional chemotherapy administrated have shown significant improvements in tumor targeting, reduced systemic toxicity, and enhanced therapeutic efficacy [10]. A similar trend is observed in MASLD where lipid-based nanoformulations are expected to give better liver targeting, decreased inflammatory reaction, and improved lipid metabolism [11].

Liposomal nanotechnology remains the most important aspect of clinical translation in the area of lipid-based carriers. The systems are known for their excellent compatibility with living organisms, their capacity to encapsulate a wide range of drug types, and their proven records of safety. Still, the new research areas are aimed at manufacturing consistency, increasing production, and surface engineering to further improve the therapeutic window of liposomal drugs [12]. These improvements, when put together, not only indicate but also confirm the increasing prominence of nanocarriers made of lipids in both clinical and research settings, especially in the areas of delivery through the mouth, targeting and general circulation.

3. Controlled Release Systems

Controlled release drug delivery systems have been developed to effectively regulate the rate, timing, and location of drug release, thus enhancing therapeutic outcomes and patient compliance. Research has pointed out that the use of these systems is very important in achieving constant plasma levels, cutting down the number of doses, and eliminating the side effects that would otherwise be experienced with conventional forms of dosing. The development of controlled release technologies has been an indication of the continuous move towards drug delivery methods which are more accurate and centered on patient needs [13]. Their use is still increasing as healthcare is looking for more efficient and reliable therapeutic interventions.

Research into oral controlled release mechanisms has been a major factor in drug delivery over prolonged periods. They have also been widely accepted in pharmaceutical form and medical practice as the drawback of rapid gastrointestinal transit is no longer a problem. A variety of techniques are being used in the modern drug formulation which includes the use of polymeric matrices, hydrophilic gels, hydrophobic barriers, and multi-layered structures to attain sustained, delayed, or pulsatile release profiles. These developments ensure that drug molecules are released at a controlled rate, thus, guaranteeing consistent therapeutic effects and less variability caused by patient-related factors like pH and motility [14]. Consequently, controlled release oral dosage forms have become a key part of chronic disease management.

The field of controlled release delivery is continuously evolving and integrating new polymers, biodegradable materials and responsive intelligent carriers. Mechanisms based on diffusion, osmotic pressure, and polymer erosion are considered essential but new methods are offering more control over drug release by the use of stimuli-responsive materials that respond to environmental conditions like pH, temperature or enzyme activity. The main advantage of these systems is that they not only improve pharmacokinetic profiles and site-specific delivery but also make the treatment of a wide variety of drugs possible [15]. Their versatility keeps them in the forefront of modern drug technology.

 doi:10.20944/preprints202511.1343.v1

In oral controlled release design, new methods and techniques such as microencapsulation, floating systems, gastroretentive devices, and mucoadhesive formulations have shown great promise. The consistent and simultaneous use of these methods is to prolong gastric residence time, improve the absorption windows, and release in specific areas of the gastrointestinal tract. Their simplicity in operation and the fact that they increase bioavailability have made them an important factor in the formulation of drug molecules that are difficult to work with because of their narrow absorption windows or instability in the lower GI segment [16]. Together with modern polymer technology, these systems make it possible to formulate drugs for both immediate and delayed therapeutic needs.

Controlled-release systems are becoming more and more the backbone of the therapies that are targeted at the gastrointestinal tract, especially in the case of cancer where the drug's impact has to be localized or the drug's exposure to the body has to be minimized. Nanotechnology-based drug carriers and polymeric delivery platforms allow the drugs to escape breaking down too early and to get to the specific regions of the GI tract with enhanced accuracy. Targeted-release profiles that are in line with the disease pathology are offered by such systems which then lead to the betterment of the disease treatment and the minimization of side effects [17]. These systems are made more viable for clinical use through the combination of the surface engineering and the designing of smart materials that respond to stimuli.

The basic mechanisms of controlled release—diffusion, dissolution, swelling, erosion, and osmotic pressure—are still the ones that provide the scientific basis for the current systems. Each mechanism has a different effect on drug release, which gives formulation scientists an opportunity to customize the drug release rate according to the drug’s properties and the treatment goal. The continuous upgrading of these principles has produced very sophisticated models that can predict the release behavior and thus provide guidance for the rational design of advanced delivery platforms [18]. All these mechanisms together form the core of the modern controlled release systems which provide consistent and predictable therapeutic performance.

4. Oral Dosage and Tablet Innovations

Quality-by-design (QbD) approaches have been the main focus of modern innovations in oral solid dosage systems to guarantee consistency in performance, better manufacturability, and increase in therapeutic efficacy. By means of the QbD frameworks, formulators are able to discern the critical material attributes and process parameters in a systematic manner, thus getting the most out of dissolution, stability, and bioavailability while keeping the variation between batches to a minimum. These strategies have become essential not only in the development of reliable but also patient-centric oral delivery systems that meet the requirements of contemporary pharmaceutical manufacturing [19].

Furthermore, tablet technology has made it possible to offer patients more experience-friendly forms such as those of the fast-dissolving, effervescent, and oral dispersible nature. The new forms of medications not only boast their patient-friendliness but also lend themselves to more delightful and enjoyable ways of consuming medicines. Their composition calls for companies that use non-standard excipients, superdisintegrants, and effervescent systems that accordingly help medications get dissolved quickly when they come into contact with either saliva or water. This got the coming generation to be patient compliant over the wide spectrum of populations consisting of children, older adults, and the ones having difficulty swallowing [20]. So, these innovations are able to bring about both the development and the expansion of therapeutic applications of the whole range of oral dosage forms.

Amongst the various technologies being used to induce the next generation of tablets, 3D-printing as well as artificial intelligence (AI) are considered to be the major ones. The former permits the exact tailoring of the dosage forms, the range of the modifications includes geometry, internal architecture, and multilayer designs, with the sole purpose of meeting the specific release profile of the patient. The breakdown of these two barriers of technology one with the help of AI-as a guide

 doi:10.20944/preprints202511.1343.v1

through predictive modeling-the other with the grace of 3D printing-as a partner to the real-time quality of dissolution, controlled drug release, and formulation robustness [20]. The merging of these two technologies is believed to completely change the face of personalized the medicine and next-generation tablet design [21]. Research done in parallel on capsule fabrication has also made targeted and programmable oral delivery possible. Newly developed capsule technologies are capable of using enteric coatings, pH-sensitive polymers, micro-manufactured shells, and enzymatically biodegradable layers to accomplish region-specific release in the gastrointestinal tract. Such delivery systems keep biosensitive or biologically active compounds safe from degradation thus, with more precision and therapeutic relevance, the payloads are delivered. Their versatility makes them indispensable for both small molecules and biopharmaceuticals [22]. Furthermore, micro- and nano-delivery systems are regarded as a potential solution for oral mucosal disorders like oral mucositis where traditional tablets and capsules are not effective. The use of nanoscale delivery carriers allow enabling localized delivery, prolonged retention and improved permeation across mucosal tissues thus providing the required therapeutic action at the site of disease. Their capability to control inflammation, restore tissue faster and make the patient comfortable supports the point that the area of oral dosage forms is challenged to come up with more ways to deliver drugs besides systemic delivery [23].

5. Synergistic and Integrated Approaches

The merging of lipid-based nanocarriers, nanoparticle systems, and modern oral dosage technologies has opened up a new era of drug delivery strategies that take full advantage of the therapeutic potential. There is a growing trend in using integrated methods that not only combine liposomes, which are vesicular carriers, with modern oral platforms, for instance, fast-dissolving and effervescent formulations but also to benefit patient convenience and drug absorption simultaneously. These hybrid designs present faster action, better bioavailability, and the stable existence of sensitive molecules, thus proving the necessity of merging different delivery principles into one therapeutic system [24].

Among these integrated frameworks, lipid-based nanoparticles, more specifically, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are very crucial owing to their biocompatibility and the ability to deliver peptides for oral administration. Their structural versatility facilitates the control of drug release, shielding from enzymatic degradation, and promoting cellular uptake hence making them very compatible with advanced oral dosage forms. SLNs and NLCs together with the formulation strategies that optimize gastrointestinal transit or enhance mucosal interaction support delivery outcomes that are synergistic and surpass the capabilities of each system alone [25].

Lipid-based nanocarrier platforms, which cover a wider spectrum, like liposomes, niosomes, and micelles, are able to add to integrated therapeutic strategies by overcoming the solubility and permeability problems of BCS class II and IV drugs. Their dual nature allows the easy trapping of poorly soluble compounds, and at the same time, their small size leads to quicker absorption through both lymph and cell pathways. With the incorporation of these carriers into tablets, capsules, or controlled release systems for oral administration, a confident and prolonged drug exposure is secured, thus supporting the argument for the merging of traditional oral technologies with advanced nanodelivery tools [26].

6. Future Directions

The field of transporter-mediated absorption is a significant one in the oral drug delivery systems, and at the same time, it is a highly demanding one. Delivery platforms of the future will have the capability to be used in combination with modified carriers and therapies that would be able to selectively and at different times stimulate the intestinal or tissue-specific transporters. Such targeting strategies will offer better therapeutic precision, less exposure to off-target areas, and

 doi:10.20944/preprints202511.1343.v1

formulation designs that will be able to tackle complex diseases faster than conventional passive systems [27].

The role of artificial intelligence in the development of oral dosage forms will be to facilitate the implementation of predictive modeling for choosing materials, dissolution behavior, and drug-excipient interactions. AI-assisted workflows through the early simulation of formulation performance and optimization of release characteristics in the design phase will be able to cut down development timelines considerably. Besides, machine learning algorithms will be responsible for designing customized dosing solutions and adaptive tablet systems, thus establishing AI as a major player in the controlled-release technologies of the future [28].

The future of capsule-based systems is seen to be more automated, more precise, and more targeted. For instance, the advent of micrometric capsules, multi-chamber structures, and predetermined breaking points for the release of drugs will greatly facilitate the selective release of drugs in particular gastrointestinal areas. The combination of these new ideas together with the development of biomaterials and nanoparticle integration will give rise to the next generation of oral drug delivery systems that will be characterized by their dependability, control over the location of delivery, and improved therapeutic results [29].

7. Foundational and Classic References

The classical drug delivery literature's basic principles are still influential in therapeutics systems' modern development. The initial models put forward by Chien underlined the necessity of controlled and sustained release, optimization of pharmacokinetics, and incorporation of physiological targeting into formulation design. These ideas are still very much present in today's innovations, supporting the use of nanocarriers, the development of oral delivery methods, and the implementation of advanced release mechanisms as part of the strategy. The fundamental insights provided in this paper are still a theoretical foundation for modern methods that aim to improve drug delivery efficiency, stability, and patient-oriented performance [30].

8. Conclusions

The present article covers the whole range of contemporary methods of drug delivery to the body and the very emphasis is on the partnership of lipid-based nanocarriers, controlled-released systems and advanced oral dosage methods as they are collectively shaping the therapeutic landscape of today and tomorrow. Theoretical foundations from classical delivery science still serve as the basis of the rational design of nanocarriers like liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) besides all other lipid-based systems that tackle solubility, permeability, and stability issues. The development of controlled-release formulations also has given rise to the very possibility of exact control over drug release kinetics by the application of a combination of diffusion-, erosion-, osmotic-, and swelling-based mechanisms leading to the enhancement of therapeutic consistency and patient compliance. Moreover, oral dosage forms and tablet technologies including but not limited to fast-dissolving tablets, effervescent systems, quality by design (QbD)-driven formulations, and the emerging 3D-printed platforms are showing the transformation of patient-friendly and customizable drug delivery approaches.

Nanocarrier technologies are increasingly found in combination with smart oral formulations in the quest for superior bioavailability, targeted delivery, and predictable pharmacokinetics. The innovations in transporter-mediated absorption, AI-guided formulation design, and next-generation capsule engineering depict the future directions where precision, personalization, and automation will be ruling oral drug delivery systems. Lastly, this paper points out that the current trend in pharmaceutical delivery is towards integrated, flexible, and technologically advanced systems that improve safety, effectiveness, and patient-centered performance, thereby laying a solid ground for future therapeutic solutions.

 doi:10.20944/preprints202511.1343.v1

References

1. Ashutosh, S. (2025). Pharmaceutical Delivery Innovations: Uniting Nanocarriers, Liposomes, Targeted Formulations, and Advancements in Tablet Technologies. Preprints. https://doi.org/10.20944/preprints202510.2043.v1
2. Ashutosh, S. (2025). Drug Delivery Research Exploring Liposomal Systems, Nanoparticle Technologies, Oral Formulations, and Controlled Release Mechanisms. Preprints. https://doi.org/10.20944/preprints202510.2284.v1
3. Sengar, A., Yadav, N., Kushwaha, P. M., & Shivam. (2025). Modern Approaches in Drug Delivery Covering Vesicular Carriers Nanoparticles Solid Lipid Systems and Innovative Oral Dosage Strategies. World Journal of Pharmaceutical Research, 14(21), 157–165. https://doi.org/10.5281/zenodo.17472277
4. Liu, P., Chen, G., & Zhang, J. (2022). A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Pharmaceutics, 14(10), 2345. https://doi.org/10.3390/pharmaceutics14102345
5. Godase, S. S., & Kulkarni, N. S. (2023). A comprehensive review on novel lipid-based nano drug delivery. Advanced Pharmaceutical Bulletin, 14(1), 34–47. https://doi.org/10.34172/apb.2024.012
6. Mehrdadi, S. (2023). Lipid-based nanoparticles as oral drug delivery systems: Overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide and protein therapeutics. Advanced Pharmaceutical Bulletin, 14(1), 48–66. https://doi.org/10.34172/apb.2024.016
7. Cho, H., Huh, K. M., Cho, H. J., Kim, B., Shim, M. S., Cho, Y., Lee, J. Y., Lee, H. S., Kwon, Y. J., & Kang, H. C. (2024). Beyond nanoparticle-based oral drug delivery: transporter-mediated absorption and disease targeting. Biomaterials Science, 12, 3045–3067. https://doi.org/10.1039/D4BM00313F
8. Godase, S. S., & Dhole, S. N. (2023). Lipid-based nano/micro formulation strategies to overcome challenges associated with poorly soluble and permeable drugs. Advanced Pharmaceutical Bulletin, 14(1), 34–47.
9. Cho, Y., Kim, B., Shim, M. S., & Lee, H. S. (2024). Lipid nanoparticles for enhancing oral bioavailability. Nanoscale Research Letters, 19, 78. https://doi.org/10.1186/s11671-024-10532-5
10. Hasan, M., Evett, C. G., & Burton, J. (2024). Advances in nanoparticle-based targeted drug delivery systems for colorectal cancer therapy: A review. Journal of Cancer Nanomedicine, 5(3), 112–131. https://doi.org/10.1007/s13346-024-01748-x
11. Zhang, Z. H., et al. (2024). Nano-drug delivery systems in metabolic dysfunction associated steatotic liver disease (MASLD): Current status and perspectives. Frontiers in Pharmacology, 15, 1419389. https://doi.org/10.3389/fphar.2024.1419389
12. Maryadele, S., & Kumar, R. (2024). Advances in liposomal nanotechnology: from concept to clinics. Physical & Materials Drug Delivery. https://doi.org/10.1039/D4PM00176A
13. Swarnalatha, K. M., Iswariya, V. T., Akash, B., Bhandari, S., Shirisha, R., & Ramarao, T. (2024). A comprehensive review of controlled drug release delivery systems: Current status and future directions. International Journal of Pharmaceutical and Phytopharmacological Research, 14(2), 24–30. https://doi.org/10.51847/d6pncGCouf
14. Swarnalatha, K. M., et al. (2024). Advances in oral controlled release drug delivery systems. Journal of Controlled Release Reviews. https://doi.org/10.1002/jcrr.2024.0475
15. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: Current status and future directions. Molecules, 26(19), 5905. https://doi.org/10.3390/molecules26195905
16. Gopaiah, K. V., Medarametala, R. T., Kumar, J. N. S., Niharika, K., Sai, V., Pavani, V., & Irfan, S. (2024). Innovations and techniques in oral controlled release drug delivery. Human Journals. https://humanjournals.com/wp-content/uploads/2024/10/2.Dr_.-K-Venkata-Gopaiah1-Ramya-Teja-Medarametala2-Dr_.-J.-N.-Suresh-Kumar3-Kilari-Niharika4-Nelapati-Venkata-Sai4-Vellaturi-Pavani4-Jampakhanala-Shaik-Irfan4-Palavai-Manjula4.pdf
17. Sahoo, C. K., & Panda, K. C. (2024). Advanced oral drug delivery systems for gastrointestinal targeted therapy. Journal of Nanobiotechnology, 23, 145. https://doi.org/10.1186/s12951-025-03479-8
18. Swarnalatha, K. M., & Iswariya, V. T. (2024). Controlled release mechanisms: diffusion, erosion, osmotic, and swelling – state of the art. International Journal of Pharmaceutical and Phytopharmacological Research, 14(3), 40–55.

 doi:10.20944/preprints202511.1343.v1

19. Atre, P. (2025). Advances in oral solid drug delivery systems: Quality by design. Innovations in Pharmaceutical Sciences, 5(2), 9. https://doi.org/10.3390/ipsci5020009
20. Atre, P., & Gupta, R. (2025). Tablet technologies: fast-dissolving, effervescent, and orally dispersible tablets in modern therapeutics. International Journal of Pharmaceutics Advances.
21. Atre, P., & Singh, A. (2025). 3D printing and AI in controlled-release tablets: The future of oral dosage forms. Journal of Pharmaceutical Innovation, 10(1), 45–60.
22. Millet, E., et al. (2025). Emerging technologies in capsule fabrication and targeted drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.2751
23. Shah, S., Rath, H., Sharma, G., Senapati, S. N., & Mishra, E. (2024). Micro and nano drug delivery systems for the treatment of oral mucositis: A review. Drug Delivery and Translational Research, 15, 2323–2353. https://doi.org/10.1007/s13346-024-01748-x
24. Ashutosh, S. (2025). Innovative Strategies in Therapeutic Delivery Including Liposomes Nanoparticles Fast Dissolving Dosage Forms and Effervescent Formulations. Preprints. https://doi.org/10.20944/preprints202511.0028.v1
25. Mehrdadi, S., & Smith, J. (2024). Lipid-based nanoparticles: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for oral peptides. Pharmaceutical Research, 41(6), 1254–1270. https://doi.org/10.1007/s11095-024-03346-7
26. Godase, S. S., Dhole, S. N., & Kulkarni, N. S. (2023). Novel lipid-based nano drug delivery: liposomes, niosomes, micelles for BCS class II & IV drugs. Advanced Pharmaceutical Bulletin, 14(1), 34–47.
27. Cho, H., Huh, K. M., Cho, H. J., & Lee, H. S. (2024). Transporter-mediated absorption and disease targeting in oral delivery systems. Biomaterials Science, 12, 3045–3067.
28. Atre, P., & Singh, A. (2025). Artificial intelligence and predictive modeling in oral dosage form development. Journal of Pharmaceutical Innovation, 10(1), 45–60.
29. Millet, E., et al. (2025). Future of capsule-based and targeted oral drug delivery technologies. European Journal of Pharmaceutics and Biopharmaceutics.
30. Chien, Y. W. (1991). Novel drug delivery systems (2nd ed.). Informa Healthcare.